trending Market Intelligence /marketintelligence/en/news-insights/trending/3GwadCQAYijenfHlbQ3L1w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Karyopharm seeks US FDA accelerated approval for cancer treatment Xpovio

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Karyopharm seeks US FDA accelerated approval for cancer treatment Xpovio

Karyopharm Therapeutics Inc. submitted a new drug application with the U.S. Food and Drug Administration seeking accelerated approval for Xpovio, or selinexor, to treat patients with diffuse large B-cell lymphoma, or DLBCL.

DLBCL is a cancer that starts in infection-fighting cells called lymphocytes and shows itself through pea-sized glands in parts of the body that are part of the immune system.

SNL Image

The Newton, Mass.-based company is seeking approval for its oral treatment in patients who are ineligible for stem cell transplants and whose DLBCL recurs or persists even after two other therapies. The treatment has received both the orphan drug and fast track designations from the FDA in this indication.

Selinexor targets cancer cells by depriving them of exportin 1, a protein used by parts of a cell to interact with each other.

In July, selinexor received accelerated approval from the FDA to treat multiple myeloma, an incurable blood cancer that forms in a type of white blood cells. In September, Karyopharm sold tiered royalty rights for selinexor to HealthCare Royalty Partners for $75 million.